MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
Hematological Oncology · 2025
DOI: 10.1002/hon.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Yan Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, c-Mer Tyrosine Kinase, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 31 Literaturangaben. Gefördert von: the Science Foundation of Henan Province, China Postdoctoral Science Foundation, Joint Co-construction Project of Henan Medical Science and Technology Research Program.
Abstract (Originalsprache)
Relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) patients do not receive standard rescue treatment; therefore, the exploration of new therapeutic targets for the treatment of DLBCL is urgently needed. Immunohistochemistry and western blotting were performed to determine the expression of MerTK in DLBCL. Targeted knockdown of MerTK by shRNA was conducted in DLBCL cell lines. DLBCL cell‐derived xenograft models were established to evaluate the effects of MerTK in vivo. We found for the first time that MerTK, a proto‐oncogene, is aberrantly highly expressed in DLBCL samples and cell lines. Targeted knockdown of MerTK or application of UNC2025, a small inhibitor of MerTK, can inhibit DLBCL cell proliferation, promote apoptosis, and inhibit G2/M phase arrest. Transcriptome sequencing was performed after targeted knockdown of MerTK, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that the differentially expressed genes involved in the autophagy pathway, in which the expression of ANXA1 was significantly upregulated, were significantly enriched. Further studies revealed that targeted MerTK knockdown inhibited autophagy flow by increasing the expression of ANXA1 in DLBCL cells. Overexpression of ANXA1 decreased proliferation and autophagy flow in DLBCL cells. Targeted knockdown of MerTK decreased disease progression in a mouse xenograft DLBCL model in vivo. UNC2025 inhibited tumor growth in a DLBCL cell‐derived xenograft model. Therefore, MerTK is ectopically expressed in DLBCL, and targeted inhibition of MerTK suppresses the growth of DLBCL in vitro and in vivo. This study provides clues for precision therapy for DLBCLs that target MerTK.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
ORCID-Profile: Jun Zhu, Mingzhi Zhang
Förderung
- the Science Foundation of Henan Province
- China Postdoctoral Science Foundation
- Joint Co-construction Project of Henan Medical Science and Technology Research Program
Zitieren
APA
Li, Y., Shi, C., Wu, J., Feng, X., Song, W., Jin, M., Chang, Y., Han, L., Zhang, P., Song, Y., Zhu, J., & Zhang, M. (2025). MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70089
Vancouver
Li Y, Shi C, Wu J, Feng X, Song W, Jin M, et al. MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70089
BibTeX
@article{Li2025,
author = {Li, Yan and Shi, Cunzhen and Wu, Jiazhuo and Feng, Xiaoyan and Song, Wenting and Jin, Mengyuan and Chang, Yu and Han, Lijuan and Zhang, Ping and Song, Yuqin and Zhu, Jun and Zhang, Mingzhi},
title = {MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70089}
}
EUVIMED